{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:01:57Z","timestamp":1790946117003,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010451","name":"Hunan Province Health Commission","doi-asserted-by":"publisher","award":["202103040800"],"award-info":[{"award-number":["202103040800"]}],"id":[{"id":"10.13039\/501100010451","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2021JJ30969"],"award-info":[{"award-number":["2021JJ30969"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2022ZZTS0953"],"award-info":[{"award-number":["2022ZZTS0953"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002822","name":"Central South University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bbrc.2025.153012","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:07:48Z","timestamp":1763640468000},"page":"153012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Exosomal circ_0058493 promotes imatinib resistance via miR-548b-3p\/U2SURP axis in CML cells"],"prefix":"10.1016","volume":"793","author":[{"given":"Bing-Jie","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Ting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Ni","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ning","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Ping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9976","key":"10.1016\/j.bbrc.2025.153012_bib1","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bbrc.2025.153012_bib2","first-page":"996","article-title":"Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase","volume":"40","author":"Yu","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.bbrc.2025.153012_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11684-018-0639-7","article-title":"Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety","volume":"13","author":"Huang","year":"2019","journal-title":"Front. Med."},{"issue":"11","key":"10.1016\/j.bbrc.2025.153012_bib4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.3324\/haematol.2017.174953","article-title":"Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia","volume":"102","author":"Geelen","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.bbrc.2025.153012_bib5","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term Follow-Up of the French stop imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"252","key":"10.1016\/j.bbrc.2025.153012_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10142-023-00980-x","article-title":"Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"23","author":"Yin","year":"2023","journal-title":"Funct. Integr. Genomics"},{"issue":"9","key":"10.1016\/j.bbrc.2025.153012_bib8","doi-asserted-by":"crossref","first-page":"6312","DOI":"10.1002\/jcp.30301","article-title":"PKC-\u03b2\/Alox5 axis activation promotes Bcr-Abl-independent TKI-Resistance in chronic myeloid leukemia","volume":"236","author":"Ma","year":"2021","journal-title":"J. Cell. Physiol."},{"issue":"7","key":"10.1016\/j.bbrc.2025.153012_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179558","article-title":"Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia","volume":"12","author":"Bandyopadhyay","year":"2017","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.bbrc.2025.153012_bib10","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.ymthe.2019.05.011","article-title":"circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p\/FOXO3a axis in breast cancer","volume":"27","author":"Sang","year":"2019","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-018-0827-8","article-title":"Circular RNAs function as ceRNAs to regulate and control human cancer progression","volume":"17","author":"Zhong","year":"2018","journal-title":"Mol. Cancer"},{"issue":"24","key":"10.1016\/j.bbrc.2025.153012_bib12","doi-asserted-by":"crossref","first-page":"6142","DOI":"10.1158\/0008-5472.CAN-21-1518","article-title":"Circ0008399 interaction with WTAP promotes assembly and activity of the m(6)A methyltransferase complex and promotes cisplatin resistance in bladder cancer","volume":"81","author":"Wei","year":"2021","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/0008-5472.CAN-21-1473","article-title":"Oncogenic circRNA C190 promotes non-small cell lung cancer via modulation of the EGFR\/ERK pathway","volume":"82","author":"Ishola","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12943-020-01208-3","article-title":"Exosomal circSHKBP1 promotes gastric cancer progression via regulating the miR-582-3p\/HUR\/VEGF axis and suppressing HSP90 degradation","volume":"19","author":"Xie","year":"2020","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.bbrc.2025.153012_bib15","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/1878-0261.12629","article-title":"Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer","volume":"14","author":"Wang","year":"2020","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13046-020-1529-9","article-title":"Exosomal circRNA-100338 promotes hepatocellular carcinoma metastasis via enhancing invasiveness and angiogenesis","volume":"39","author":"Huang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2025.153012_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117255","article-title":"Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia","volume":"243","author":"Cao","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s10020-021-00395-z","article-title":"Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145\/miR-203\/ABL1 and circ 0051886\/miR-637\/ABL1","volume":"27","author":"Lu","year":"2021","journal-title":"Mol. Med."},{"key":"10.1016\/j.bbrc.2025.153012_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.728916","article-title":"CircRNA microarray profiling reveals hsa_circ_0058493 as a novel biomarker for imatinib-resistant CML","volume":"12","author":"Zhong","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbrc.2025.153012_bib20","first-page":"353","article-title":"The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2020 edition)","volume":"41","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"15","key":"10.1016\/j.bbrc.2025.153012_bib21","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41388-018-0619-z","article-title":"Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7","volume":"38","author":"Zhang","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13046-021-01942-6","article-title":"Warburg effect-promoted exosomal circ_0072083 releasing up-regulates NANGO expression through multiple pathways and enhances temozolomide resistance in glioma","volume":"40","author":"Ding","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.bbrc.2025.153012_bib23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/cr.2015.82","article-title":"Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis","volume":"25","author":"Li","year":"2015","journal-title":"Cell Res."},{"issue":"10","key":"10.1016\/j.bbrc.2025.153012_bib24","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1002\/ijc.32331","article-title":"U2-related proteins CHERP and SR140 contribute to colorectal tumorigenesis via alternative splicing regulation","volume":"145","author":"Wang","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"5","key":"10.1016\/j.bbrc.2025.153012_bib25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/FPC.0b013e328351f3e9","article-title":"Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression","volume":"22","author":"Benito","year":"2012","journal-title":"Pharmacogenet. Genom."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153012_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"issue":"20","key":"10.1016\/j.bbrc.2025.153012_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012271","article-title":"Non-coding RNAs are implicit in chronic myeloid leukemia therapy resistance","volume":"23","author":"Rudich","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-023-01452-2","article-title":"Exosomal circRNA: emerging insights into cancer progression and clinical application potential","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.bbrc.2025.153012_bib29","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.ymthe.2022.01.022","article-title":"Exosome-derived circTRPS1 promotes malignant phenotype and CD8+ T cell exhaustion in bladder cancer microenvironments","volume":"30","author":"Yang","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbrc.2025.153012_bib30","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","article-title":"Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.bbrc.2025.153012_bib31","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.yexcr.2017.12.001","article-title":"Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365","volume":"362","author":"Min","year":"2018","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bbrc.2025.153012_bib32","first-page":"3105","article-title":"MiR-548b-3p inhibits proliferation and migration of breast cancer cells by targeting MDM2","volume":"24","author":"Sha","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.bbrc.2025.153012_bib33","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s10103-019-02865-7","article-title":"miR-548b-3p functions as a tumor suppressor in lung cancer","volume":"35","author":"Wang","year":"2020","journal-title":"Laser Med. Sci."},{"key":"10.1016\/j.bbrc.2025.153012_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118743","article-title":"KPNA4 regulated by miR-548b-3p promotes the malignant phenotypes of papillary thyroid cancer","volume":"265","author":"Feng","year":"2021","journal-title":"Life Sci."},{"issue":"23","key":"10.1016\/j.bbrc.2025.153012_bib35","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-10-2034","article-title":"Persistent activation of the Fyn\/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC","volume":"70","author":"Fenouille","year":"2010","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbrc.2025.153012_bib36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1878-0261.12186","article-title":"Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-\u03baB pathways in a model of chronic myeloid leukemia","volume":"12","author":"Chorzalska","year":"2018","journal-title":"Mol. Oncol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25017280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X25017280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T14:17:40Z","timestamp":1773843460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X25017280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S0006291X25017280"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153012","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exosomal circ_0058493 promotes imatinib resistance via miR-548b-3p\/U2SURP axis in CML cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2025.153012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153012"}}